There’s a lot of enthusiasm about Active Surveillance (AS) for prostate cancer (PCa) patients with low or very low risk disease. In fact, many doctors are even discussion AS with their patients who have a Gleason 3+4 tumor; however, much controversy exists over the question of whether AS is a safe option for these patients. keep reading
A diagnosis of prostate cancer (PCa) can be shocking, even when the cancer is early stage, localized, and considered highly treatable. A secondary shock wave hits when the patient finds out he has a number of treatment choices, but they all have a variety of trade-offs. Suddenly, the man’s fate lies in his own hands keep reading
It’s been 5 years since the U.S. Preventive Services Task Force (USPSTF) demoted the PSA test to grade D, and recommended against broad screening for men of any age. Now they have backpedaled. They currently support individual physician-patient discussions about PSA for men ages 55-69. Why? Because the fears of doctors are coming true. Men keep reading
An update on COVID-19: Your health and safety are our top priority.